Adocia Announces Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets

Rhea-AI Summary

Adocia, listed on Euronext Paris under the ticker ADOCY, reported key updates regarding its liquidity agreement with Kepler Capital Markets. As of June 30, 2022, the liquidity account held 32,721 shares and a cash balance of €98,519.91. For the first half of 2022, the company bought 80,014 shares for €443,321.21 and sold 87,109 shares for €476,728.77. The liquidity agreement adheres to the AMF Decision n° 2021-01, highlighting Adocia's ongoing market practices.

Positive

• Total buy transactions in H1 2022 reached 429, contributing to improved liquidity.
• Active trading in shares showed a sell-side volume of 87,109 shares worth €476,728.77.

Negative

• The liquidity account's share count decreased from 39,816 on December 31, 2021, indicating potential liquidity challenges.
• The cash balance growth from €65,112.35 to €98,519.91 is modest compared to trading volumes.

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30^th, 2022:

• Number of shares : 32,721
• Cash balance of the liquidity account: € 98,519.91

During the first half of 2022, a total of:

Buy side	80,014 shares	€ 443,321.21	429 transactions
Sell side	87,109 shares	€ 476,728.77	331 transactions

The following resources appeared on the last half year statement on December 31, 2021 on the liquidity account:

• Number of shares : 39,816
• Cash balance of the liquidity account: € 65,112.35

The following resources appeared on the liquidity account when the activity started:

• Number of shares : 15,026
• Cash balance of the liquidity account: € 300,000.00

The liquidity agreement complies with AMF Decision n° 2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:

1) The BioChaperone^® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral^®, an oral peptide delivery technology; 3) AdoShell^® Islets, an immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.

Adocia holds more than 25 patent families.

Based in Lyon, the company has 115 employees. Adocia is listed on the Euronext^TM Paris market (Euronext: ADOC; ISIN: FR0011184241).

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005392/en/

Adocia

Gérard Soula

CEO

contactinvestisseurs@adocia.com

Tel : +33 4 72 610 610

www.adocia.com

Adocia Press and Investors Relations

Ulysse Communication

Pierre-Louis Germain

Margaux Puech Pays d’Alissac

Bruno Arabian

adocia@ulysse-communication.com

+33 (0)6 64 79 97 51

Source: Adocia

FAQ

What are the latest figures for Adocia's liquidity account as of June 30, 2022?

As of June 30, 2022, Adocia's liquidity account held 32,721 shares and a cash balance of €98,519.91.

How many shares did Adocia buy and sell in the first half of 2022?

In the first half of 2022, Adocia bought 80,014 shares and sold 87,109 shares.

What was the total transaction value for Adocia's share buybacks in H1 2022?

The total value for share buybacks in H1 2022 was €443,321.21.

What compliance does Adocia's liquidity agreement follow?

Adocia's liquidity agreement complies with AMF Decision n° 2021-01, maintaining accepted market practices.